Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04619797
Title A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-squamous non-small cell carcinoma

Therapies

Atezolizumab + Pemetrexed Disodium + Tiragolumab

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab + Pemetrexed Disodium

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab

Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

Additional content available in CKB BOOST